ClinicalTrials.gg
CompletedNCT03636204Updated Jul 27, 2020

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

A Phase 1 interventional study of AL001 and Placebo in Healthy and Frontotemporal Dementia, sponsored by Alector Inc.. Completed at 8 sites in 3 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-27.

Sponsored by Alector Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Enrollment
31st of 66
64 · median 60
Started
2018
with 5 others
Phase 1
8 of 103
1 open now
Registered
46th of 103
by date
Lead sponsor
4 of 103
Alector Inc.

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 31st largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2018, is one of 8 in phase 1, and was the 46th registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

A first in human phase 1 study in healthy volunteers and participants with Granulin (GRN) mutation causative of frontotemporal dementia (FTD) to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics

Read the detailed description

This is a first-in-human Phase 1 study designed to investigate the safety, tolerability, PK and PD of intravenously administered AL001 in Healthy Volunteers and FTD-GRN mutation carriers.

03

Conditions studied

  • Healthy
  • Frontotemporal Dementia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18.0-35.0 kg/m2
  • 45-120 kg, inclusive
  • At screening, females must be non-pregnant and non-lactating, or of nonchildbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1-year (amenorrhoea duration of 12 consecutive months); nonpregnancy will be confirmed for all females by a pregnancy test conducted at screening, (each) admission, and at follow-up.
  • Female participants of must agree to use adequate from screening until 90 days after the follow-up visit.
  • In good physical health on the basis of no findings from medical history, physical examination (PE), laboratory tests, 12 lead , and vital signs, as judged by the Investigator.
  • Willingness and able to comply with the study protocol, in the investigator's judgement.

Exclusion criteria

Exclusion Criteria:

  • Known history of severe allergic, anaphylactic, or other reactions to chimeric, human, or humanized antibodies or fusion proteins.
  • Positive drug or alcohol at screening and prior to first dose
  • History of alcohol abuse or substance abuse
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    AL001

    Up to six single ascending doses of AL001

    Biological: AL001

  • Placebo comparator
    Saline Solution

    Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects

    Other: Placebo

Interventions

  • BiologicalAL001

    Active dose of AL001

  • OtherPlacebo

    Saline solution administered as a single infusion as palcebo.

06

What researchers measure

Primary outcomes

  1. Evaluation of safety and tolerability of AL001 measured by number of subjects with adverse events and Dose Limiting Adverse Event (DLAEs)

    Incidence of adverse events and dose limiting Adverse Events during the DLAE observation period and/or study treatment periods.

    Time frame: 85 days

Secondary outcomes

  1. Pharmacokinetics (PK) of AL001

    Serum and cerebrospinal fluid (CSF) concentration of AL001 at specified time points

    Time frame: 85 days

  2. Maximum plasma concentration (Cmax) for AL001

    Evaluate Cmax for serum and CSF concentration of AL001 at specified time points

    Time frame: 85 days

  3. Area under the curve concentration (AUC) for AL001

    Evaluate AUC for serum and CSF concentration of AL001 at specified time points

    Time frame: 85 days

07

Study locations

8 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • UCSF
    San Francisco, California 94158, United States
  • Study site
    Orlando, Florida 32806, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Lawson Health Research Institute, St. Joseph's
    London, Ontario, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Canada
  • University College London
    London, WC1N 3BG, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Dec 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2018
First posted
Aug 17, 2018
StartActual
Sep 14, 2018
Primary completionActual
Dec 31, 2019
CompletionActual
Dec 31, 2019
Last update
Jul 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03636204
Lead sponsor
Alector Inc.
Responsible party
Sponsor
First posted
Aug 17, 2018
Start date
Sep 14, 2018
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Last update
Jul 27, 2020

Study contacts

George Stoica
principal investigator · Bioclinica Research

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Latozinemab

Start the discussion